ADARx Pharmaceuticals, Inc. Form 424B4 — Sep 25, 2026
ADARx Pharmaceuticals priced its IPO at $17.00 per share, selling 26,250,000 shares for gross proceeds of $446.25 million ($415.0 million net before expenses), with listing on Nasdaq under the symbol ADRX. Underwriters hold a 30-day option for up to 3,937,500 additional shares. AbbVie is purchasing 5,233,264 shares in a concurrent private placement at the IPO price, capped at $100.0 million, which would give AbbVie roughly 4.9% of shares outstanding after closing. AbbVie already paid ADARx a $335.0 million upfront fee in May 2025 under a siRNA collaboration with up to $7.45 billion in additional milestones plus tiered royalties.
Key figures
- Greenshoe
- 3937500
- Gross Proceeds
- 446250000
- Offering Price
- 17
- Shares Offered
- 26250000
- Abb Vie Shares
- 5233264
- Abb Vie Max Milestones
- 7450000000
- Abb Vie Private Placement Cap
- 100000000
- Net Proceeds Before Expenses
- 415012500
- Underwriting Discount Total
- 31237500
- Abb Vie Post Offering Ownership
- approximately 4.9%
- Abb Vie Upfront Payment May2025
- 335000000
- Reserved Directed Share Percent
- 2%
- Underwriting Discount Per Share
- 1.19
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.